TY - JOUR AU - Abreu Lomba , A. AU - González Bermúdez, C. AU - Salazar, LC AU - Bolena Muriel , A. AU - Gómez, MC AU - Hernández-Carrillo, M. PY - 2021/06/14 Y2 - 2024/03/29 TI - Non-classic adrenal hyperplasia, laboratory characteristics and treatment response. Cohort study JF - Revista Colombiana de Endocrinología, Diabetes & Metabolismo JA - Rev.ACE VL - 7 IS - 4 SE - Original Articles DO - 10.53853/encr.7.4.649 UR - https://revistaendocrino.org/index.php/rcedm/article/view/649 SP - 236-242 AB - <p><strong><em>Objective: </em></strong><em>To compare the laboratory characteristics and response to treatment in a cohort of patients with non-classical congenital adrenal hyperplasia followed during 12 months. </em></p><p><strong><em>Methods:</em></strong><em> A study was conducted in a cohort of 38 patients with non-classical adrenal hyperplasia from January 2006 to December 2016. The characteristics of the study population and the response of 17-hydroxyprogesterone (17-OH progesterone), testosterone, and dehydroepiandrosterone sulfate (DHEA-S) are reported 6 and 12 months after treatment with dexamethasone, and ethinyl estradiol/cyproterone acetate. A multiple linear regression analysis was performed in order to explain the change of the outcome variables (17-OH progesterone, testosterone, and DHEA-S), adjusted according to body mass index (BMI) and age as covariates. </em></p><p><strong><em>Results: </em></strong><em>The average age of the participants was 25 years and average BMI was 28.3 kg/m<sup>2</sup>. The most prevalent clinical features were acne (52.6%) and oligomenorrhea (55%). Hirsutism occurred to some degree in all cases (31.6% moderate and 39.5% severe, according to the Ferriman-Gallwey scale). The change in the levels of each hormone reflected a significant decrease in the median and interquartile range levels of 17-OH progesterone, testosterone and DHEA-S, at 6 and 12 months (p &lt;0.05). In the multiple linear regression, the levels of testosterone showed variation according to BMI (p = 0.04). In this study, pharmacological therapy with dexamethasone was applied at different doses and all patients were given contraceptives, with adequate clinical and paraclinical response at 1 year of follow-up. </em></p><p><strong><em>Conclusion: </em></strong><em>This study suggests that the combination of cyproterone plus ethinyl estradiol with variable doses of dexamethasone decreases the androgenic profile in patients with non-classic adrenal hyperplasia followed over a 1-year period.</em></p> ER -